Insider Trading Alert - SF, SJI And ABT Traded By Insiders

Stocks with insider trader activity include SF, SJI and ABT
By James Giaquinto ,

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Friday, March 13, 2015, 81 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $49.00 to $18,216,528.97.

Highlighted Stocks Traded by Insiders:

Stifel Financial (SF) - FREE Research Report

Dubinsky John P, who is Director at Stifel Financial, sold 1,500 shares at $55.89 on March 13, 2015. Following this transaction, the Director owned 33,443 shares meaning that the stake was reduced by 4.29% with the 1,500-share transaction.

Beda Bruce A, who is Director at Stifel Financial, sold 5,343 shares at $55.92 on March 13, 2015. Following this transaction, the Director owned 42,671 shares meaning that the stake was reduced by 11.13% with the 5,343-share transaction.

The shares most recently traded at $55.77, down $0.15, or 0.27% since the insider transaction. Historical insider transactions for Stifel Financial go as follows:

  • 4-Week # shares sold: 67,945
  • 12-Week # shares sold: 67,945
  • 24-Week # shares sold: 106,939

The average volume for Stifel Financial has been 524,600 shares per day over the past 30 days. Stifel Financial has a market cap of $3.8 billion and is part of the financial sector and financial services industry. Shares are up 9.02% year-to-date as of the close of trading on Friday.

Stifel Financial Corp., a financial holding company, provides retail and institutional wealth management, and investment banking services primarily in the United States. The company has a P/E ratio of 23.9. Currently, there is 1 analyst who rates Stifel Financial a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SF - FREE

TheStreet Quant Ratings

rates Stifel Financial as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Stifel Financial Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

South Jersey Industries (SJI) - FREE Research Report

Sims Frank L, who is Director at South Jersey Industries, bought 5,000 shares at $52.60 on March 13, 2015. Following this transaction, the Director owned 34,137 shares meaning that the stake was boosted by 17.16% with the 5,000-share transaction.

The shares most recently traded at $54.09, up $1.49, or 2.75% since the insider transaction. Historical insider transactions for South Jersey Industries go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 300
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 300
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 300

The average volume for South Jersey Industries has been 160,000 shares per day over the past 30 days. South Jersey Industries has a market cap of $1.8 billion and is part of the utilities sector and utilities industry. Shares are down 9.15% year-to-date as of the close of trading on Friday.

South Jersey Industries, Inc., through its subsidiaries, provides energy related products and services. It engages in the purchase, transmission, and sale of natural gas. The stock currently has a dividend yield of 3.74%. The company has a P/E ratio of 18.3. Currently, there are 2 analysts who rate South Jersey Industries a buy, 1 analyst rates it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SJI - FREE

TheStreet Quant Ratings

rates South Jersey Industries as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, growth in earnings per share and increase in net income. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

South Jersey Industries Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Abbott Laboratories (ABT) - FREE Research Report

Doyle Katherine C., who is Senior Vice President at Abbott Laboratories, bought 147 shares at $37.52 on March 13, 2015. Following this transaction, the Senior Vice President owned 43,474 shares meaning that the stake was boosted by 0.34% with the 147-share transaction.

The shares most recently traded at $47.66, up $10.14, or 21.27% since the insider transaction. Historical insider transactions for Abbott Laboratories go as follows:

  • 4-Week # shares sold: 23,674
  • 12-Week # shares sold: 72,382
  • 24-Week # shares sold: 72,382

The average volume for Abbott Laboratories has been 5.6 million shares per day over the past 30 days. Abbott Laboratories has a market cap of $71.3 billion and is part of the health care sector and health services industry. Shares are up 4.13% year-to-date as of the close of trading on Friday.

Abbott Laboratories manufactures and sells health care products worldwide. The stock currently has a dividend yield of 2.03%. The company has a P/E ratio of 42.2. Currently, there are 13 analysts who rate Abbott Laboratories a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ABT - FREE

TheStreet Quant Ratings

rates Abbott Laboratories as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Abbott Laboratories Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null

Loading ...